Added to YB: 2024-12-04
Pitch date: 2024-12-02
TMDX [bullish]
TransMedics Group, Inc.
-10.68%
current return
Author Info
No bio for this author
Company Info
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Market Cap
$2.2B
Pitch Price
$77.08
Price Target
200.00 (+190%)
Dividend
N/A
EV/EBITDA
19.63
P/E
14.38
EV/Sales
4.12
Sector
Health Care Equipment and Supplies
Category
turnaround
Why $TMDX Could Be 2025’s Breakout Stock
TMDX: Revolutionary organ transplant tech, 50% dip on Q3 miss (rev $108M, EPS $0.12). Temporary aviation/logistics issues squeezed margins. Long-term outlook strong: 10K transplants by 2028 ($1B rev), 20% EBITDA margins. No direct competitors. $200 price target.
Read full article (2 min)